CA3202397A1 - Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof - Google Patents

Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof

Info

Publication number
CA3202397A1
CA3202397A1 CA3202397A CA3202397A CA3202397A1 CA 3202397 A1 CA3202397 A1 CA 3202397A1 CA 3202397 A CA3202397 A CA 3202397A CA 3202397 A CA3202397 A CA 3202397A CA 3202397 A1 CA3202397 A1 CA 3202397A1
Authority
CA
Canada
Prior art keywords
fusion protein
terminus
collagen
operably linked
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3202397A
Other languages
English (en)
French (fr)
Inventor
Naveen MEHTA
Michaelson JENNIFER
Patrick Baeuerle
Bochong LI
K. Dane Wittrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cullinan Amber Corp
Original Assignee
Cullinan Amber Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullinan Amber Corp filed Critical Cullinan Amber Corp
Publication of CA3202397A1 publication Critical patent/CA3202397A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3202397A 2020-12-18 2021-12-17 Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof Pending CA3202397A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127995P 2020-12-18 2020-12-18
US63/127,995 2020-12-18
PCT/US2021/064224 WO2022133326A1 (en) 2020-12-18 2021-12-17 Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof

Publications (1)

Publication Number Publication Date
CA3202397A1 true CA3202397A1 (en) 2022-06-23

Family

ID=82058332

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3202397A Pending CA3202397A1 (en) 2020-12-18 2021-12-17 Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof

Country Status (11)

Country Link
US (1) US20240101630A1 (https=)
EP (1) EP4262840A4 (https=)
JP (1) JP2024500870A (https=)
KR (1) KR20230124633A (https=)
CN (1) CN116887850A (https=)
AU (1) AU2021400761A1 (https=)
CA (1) CA3202397A1 (https=)
IL (1) IL303712A (https=)
MX (1) MX2023007326A (https=)
WO (1) WO2022133326A1 (https=)
ZA (1) ZA202306571B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2025049528A1 (en) * 2023-08-29 2025-03-06 Cullinan Amber Corp. Combination therapies for cancer
WO2025245169A1 (en) * 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
WO2025255560A1 (en) * 2024-06-07 2025-12-11 Rush University Medical Center Intranasal p40 monomer and anti-p40 homodimer mab for type 1 diabetes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073661A1 (fr) * 2005-12-26 2007-07-05 Yantai Zhenghai Bio-Technology Co., Ltd. Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee
CA2957717C (en) * 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US12084495B2 (en) * 2016-08-03 2024-09-10 Nextcure, Inc. Compositions and methods for modulating LAIR signal transduction
HUE070957T2 (hu) * 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
AU2019232729B2 (en) * 2018-03-05 2024-08-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
US10786438B2 (en) * 2018-04-27 2020-09-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
AU2019335014A1 (en) * 2018-09-05 2021-03-25 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
WO2020186111A2 (en) * 2019-03-12 2020-09-17 xCella Biosciences, Inc. Vista-binding antibodies and uses thereof

Also Published As

Publication number Publication date
KR20230124633A (ko) 2023-08-25
IL303712A (en) 2023-08-01
MX2023007326A (es) 2023-08-22
EP4262840A1 (en) 2023-10-25
ZA202306571B (en) 2024-11-27
CN116887850A (zh) 2023-10-13
WO2022133326A1 (en) 2022-06-23
AU2021400761A1 (en) 2023-07-06
JP2024500870A (ja) 2024-01-10
US20240101630A1 (en) 2024-03-28
EP4262840A4 (en) 2024-11-20
AU2021400761A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
CA3202397A1 (en) Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof
CA3044556C (en) Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
JP7611173B2 (ja) 組換えｆａｐ結合タンパク質及びそれらの使用
US12378295B2 (en) Rationally designed protein compositions
CN107530419B (zh) 治疗疾病的组合疗法
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
JP2019528683A (ja) 多量体ｇｉｔｒ結合分子及びその使用
RS60996B1 (sr) Interleukin 15 proteinski kompleks i njegova upotreba
JP2009542592A (ja) Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
CN112513077B (zh) 高效表达的egfr和pd-l1双特异性结合蛋白
KR20250160456A (ko) Tnf 슈퍼패밀리 멤버 면역사이토카인 및 이의 용도
CN118255899A (zh) 一种IL2-IL2Rα异源复合物蛋白及其衍生物
JP2023538902A (ja) 操作されたリガンドを使用する材料及び方法
KR102655850B1 (ko) Il2 변이체 및 이를 포함하는 단백질 복합체
US20250144178A1 (en) Pharmaceutical composition for cancer treatment comprising fusion protein including il-12 and anti-fap antibody and anticancer agent
HK1262220A1 (en) Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
HK1262220B (en) Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
BR112020013854B1 (pt) Proteínas bifuncionais que combinam bloqueio de ponto de verificação para a terapia alvejada

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241118

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241118

R15 Change to inventor requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED

Effective date: 20250710

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251113

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251113

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251201

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251201

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260129

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129